Wang Jian-li, Zheng Yu-ling, Wang Bao-li, Guo Ai-guang, Ma Ru, Jiang Yong-qiang
Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2006 Jan;22(1):74-7.
To construct the expression vector of a recombinant toxin composed of a disulfide stable single-chain antibody from mAb B3 and PE38 and examine the binding ability and cytotoxicity of the purified renatured products against the B3 positive carcinoma cells.
The V(H) and V(L) fragments of the mAb B3 were ligated by overlaping PCR and the resulting product was cloned to the pET22b expression vector. The PE38 fragment was inserted into the B3dsscFv-pET22b expression vector which was digested by EcoR I and Hind III. The identified expression plasmid was tansformed into E.coli BL21(DE3) followed by IPTG induction. The inclusion body was purified through Q-Sepharose anion exchange column after denaturing and refolding. The binding and cytotoxic ability of the purified products were examined by cell-ELISA and Non-Radioactive Cell Proliferation Assay seperately. The stability assay was performed by incubating the protein sample at 37degrees Celsius.
The expression vector B3dsscFv-PE38-pET was constructed successfully and the expression product existed mainly in the form of inclusion body, accounting for 45% of the totle protein. The refolding product remained the binding ability of the single-chain antibody and exerted cytotoxic effect on HT-29 colon carcinoma cells. The stability assay showed that the resulting protein was stable at 37degrees Celsius.
This genetically engineered B3dsscFv-PE38 fusion protein was stable and bifunctional, tumor targeting and tumor cell killing, supporting that it would be a promising candidate for tumor targeted immunotherapy.
构建由单克隆抗体B3的二硫键稳定单链抗体与PE38组成的重组毒素表达载体,并检测纯化复性产物对B3阳性癌细胞的结合能力和细胞毒性。
通过重叠PCR连接单克隆抗体B3的V(H)和V(L)片段,并将所得产物克隆到pET22b表达载体中。将PE38片段插入经EcoR I和Hind III酶切的B3dsscFv-pET22b表达载体中。将鉴定后的表达质粒转化至大肠杆菌BL21(DE3),经IPTG诱导表达。变性复性后通过Q-Sepharose阴离子交换柱纯化包涵体。分别通过细胞ELISA和非放射性细胞增殖试验检测纯化产物的结合能力和细胞毒性。通过在37℃孵育蛋白样品进行稳定性试验。
成功构建表达载体B3dsscFv-PE38-pET,表达产物主要以包涵体形式存在,占总蛋白的45%。复性产物保留了单链抗体的结合能力,并对HT-29结肠癌细胞发挥细胞毒性作用。稳定性试验表明所得蛋白在37℃稳定。
这种基因工程化的B3dsscFv-PE38融合蛋白稳定且具有双功能,即肿瘤靶向性和肿瘤细胞杀伤性,表明它有望成为肿瘤靶向免疫治疗的候选药物。